M2 TAMs mediate the resistance of CRC cells to 5-FU through the PI3K/AKT signaling pathway by secreting chemokine ligand 22 (CCL22), and this effect can be inhibited by a CCL22-neutralizing antibody and the AKT inhibitor LY294002.[90] Endocrine therapy is the cornerstone treatment for patients with estrogen receptor-positive breast cancer. The gene discussed is CCL22; the disease is colorectal carcinoma.